HI SCR172

Urges the U.S. Food and Drug Administration, U.S. Surgeon General, and Hawaii's congressional delegation to consider requiring warning labels on products containing oxybenzone that address human health risks.

Identifies oxybenzone as a chemical commonly found in sunscreen and personal care products with research indicating negative impacts on human health, including hormone mimicking effects and accumulation in fatty tissues.

Notes that in utero exposure to oxybenzone has been associated with Hirschsprung's disease and that oxybenzone can transfer to infants via breast milk.

States that the FDA's most recent safety evaluation of oxybenzone was published in 1999 and current labeling requirements do not include warnings about potential harm from oxybenzone exposure.

Directs certified copies be transmitted to the FDA Commissioner, U.S. Surgeon General, Hawaii's congressional delegation, and Hawaii state directors of Health and Commerce and Consumer Affairs.